{
  "ticker": "CRVS",
  "company_name": "Corvus Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma",
      "start_date": "2018-04-25",
      "completion_date": "2023-02-19",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02655822",
      "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer",
      "start_date": "2016-01",
      "completion_date": "2021-07",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04464395",
      "title": "Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "COVID-19",
      "start_date": "2020-07-01",
      "completion_date": "2021-07-09",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06345404",
      "title": "Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Atopic Dermatitis",
      "start_date": "2024-04-23",
      "completion_date": "2025-11",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03952078",
      "title": "A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "T-cell Lymphoma",
      "start_date": "2019-05-03",
      "completion_date": "2026-04-30",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04280328",
      "title": "Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma",
      "start_date": "2020-02-20",
      "completion_date": "2022-03-01",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06561048",
      "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell",
      "start_date": "2024-10-02",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03237988",
      "title": "Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Subjects",
      "start_date": "2017-07-20",
      "completion_date": "2017-10-04",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04734873",
      "title": "CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Covid-19",
      "start_date": "2021-02-25",
      "completion_date": "2021-08-18",
      "enrollment": 0,
      "sponsor": "Corvus Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 9,
    "by_phase": {
      "PHASE1": 7,
      "PHASE3": 2
    },
    "by_status": {
      "COMPLETED": 5,
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "TERMINATED": 1
    },
    "active_trials": 3,
    "completed_trials": 5,
    "conditions": [
      "Atopic Dermatitis",
      "COVID-19",
      "Covid-19",
      "Healthy Subjects",
      "Multiple Myeloma",
      "Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma",
      "Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell",
      "Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer",
      "T-cell Lymphoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:45.382229",
    "search_query": "Corvus Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Corvus+Pharmaceuticals,+Inc."
  }
}